Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
Loading...
Date
2022-09-17
Journal Title
Journal ISSN
Volume Title
Publisher
The Lancet HIV
Abstract
Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg.
Description
Keywords
Citation
Amuge, P., Lugemwa, A., Wynne, B., Mujuru, H. A., Violari, A., Kityo, C. M., ... & Goodman, A. (2022). Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. The Lancet HIV, 9(9), e638-e648.